Merge branch 'main' of https://gitlab.igem.org/2023/lambert-ga

src/pages/description.mdx

@@ -36,11 +36,11 @@ Currently, various detection and diagnosis methods are used for CAD. These inclu
 Coronary artery disease is caused by plaque buildup which is initially clustered in fat and blood cells in the body (see Fig. 2). As the collection worsens, arteries narrow in a process called atherosclerosis. The following describes the key process in three crucial steps from the normal condition of the artery (Shahjehan, 2023).
 
 <div className="pl-2">
- Formation - The first stages of the formation of atherosclerosis include the deposition of foam cells, also known as lipid macrophages (CDC, 2021). They disrupt the tunica intima, which is the innermost layer of the artery. Due to this disruption, a “fatty streak” is formed. 
+ Formation - The first stages of the formation of atherosclerosis include the deposition of foam cells, also known as lipid macrophages. They disrupt the tunica intima, which is the innermost layer of the artery. Due to this disruption, a “fatty streak” is formed (CDC, 2021).
 
- Progression - The progression of low-density lipoprotein (LDL) particles and foam cells activate T cells, a type of white blood cell that leads to immune responses promoting the nourishment of the plaque (CDC, 2021). Thus, the plaque’s size increases and this process is known as angiogenesis (CDC, 2021). 
+ Progression - The progression of low-density lipoprotein (LDL) particles and foam cells activate T cells, a type of white blood cell that leads to immune responses promoting the nourishment of the plaque. Thus, the plaque’s size increases and this process is known as angiogenesis (CDC, 2021). 
 
- Blockage - As the plaque continues to grow, it undergoes calcification which leads to the narrowing of the coronary arteries and restriction of blood flow (CDC, 2021). If there is complete blockage in the arteries, there is a severe chance of myocardial infarction, or a heart attack (CDC, 2021).
+ Blockage - As the plaque continues to grow, it undergoes calcification which leads to the narrowing of the coronary arteries and restriction of blood flow. If there is complete blockage in the arteries, there is a severe chance of myocardial infarction, or a heart attack (CDC, 2021).
 </div>
 
 <Image src='https://static.igem.wiki/teams/4683/wiki/homepage/pathophys.png' caption='Figure 2. The progression of CAD' />

src/pages/human-practices.mdx

@@ -18,7 +18,9 @@ import Reference from "../components/md_components/Reference";
 
 Last year, Lambert iGEM identified patients as the end goal of CADlock’s implementation. In order to accomplish this, we interviewed multiple leading microRNA researchers and cardiologists, who contributed to identifying the direction of our project as a point-of-care diagnostic screening tool to track the progression of coronary artery disease (CAD). Inspired to expand last year’s project with a focus on inclusivity, we improved and implemented wet lab mechanisms, including exponential rolling circle amplification (eRCA) from RCA [see RCA](https://2023.igem.wiki/lambert-ga/rca/). We also used protein purification to create our own phi29 DNA polymerase to minimize reaction costs. In addition, we expanded upon MicroQ, implementing an adaptation called MicroQ Pro. Furthermore, after talking with a graduate student, we developed LabPilot, an automated pipetter. We created a podcast and spoke to multiple doctors and professionals about the direction of our project. Drawing on the expertise of exceptional stakeholders, our journey transformed from conceptualization to implementation (see Fig. 1). 
 
-<Image src='https://static.igem.wiki/teams/4683/wiki/human-practices/hp-graphic-1.png' caption='Figure 1. Overview graphic of the 2023 inclusivity approach.' />
+<Image src='https://static.igem.wiki/teams/4683/wiki/human-practices/hp-graphic-1.png' 
+size="800"
+caption='Figure 1. Overview graphic of the 2023 inclusivity approach.' />
 
 
 ## Doctors
@@ -27,7 +29,8 @@ Last year, Lambert iGEM identified patients as the end goal of CADlock’s imple
 
 We spoke to Dr. Mindy B. Gentry, a cardiologist in Marietta, Georgia,  about sex inclusivity and CAD. We originally planned to use a gene called SVEP1, a gene that influences atherosclerosis. Specifically, SVEP1 expresses a protein that stimulates the development of plaque in arteries. This gene has a negative correlation with a miRNA named miR-1269b.  Instead, she guided us to look at CAD correlation with an emphasis on estrogen-induced pathways. With her help, we were able to find a correlation between CAD and an estrogen-specific miRNA. Dr. Gentry, who runs a female cardiac health center, expressed the need for proactive measures to be taken to preserve heart health for females. The incorporation of Lambert iGEM’s estrogen initiative, guided by her aid, strengthens the proactive approach by making a diagnostic for a specialized risk group.
 
-<Image src='https://static.igem.wiki/teams/4683/wiki/human-practices/gentry.png' caption='Figure 2. Dr. Mindy B. Gentry' />
+<Image src='https://static.igem.wiki/teams/4683/wiki/human-practices/gentry.png' 
+caption='Figure 2. Dr. Mindy B. Gentry' />
 
 ### Dr. Fairweather